Akademska digitalna zbirka SLovenije - logo
E-viri
Celotno besedilo
Recenzirano Odprti dostop
  • Coronavirus-Specific Antibo...
    Komissarov, Alexey A; Kislova, Maria; Molodtsov, Ivan A; Petrenko, Andrei A; Dmitrieva, Elena; Okuneva, Maria; Peshkova, Iuliia O; Shakirova, Naina T; Potashnikova, Daria M; Tvorogova, Anna V; Ptushkin, Vadim V; Efimov, Grigory A; Nikitin, Eugene A; Vasilieva, Elena

    International journal of molecular sciences, 12/2022, Letnik: 24, Številka: 1
    Journal Article

    The clinical course of the new coronavirus disease 2019 (COVID-19) has shown that patients with chronic lymphocytic leukemia (CLL) are characterized by a high mortality rate, poor response to standard treatment, and low virus-specific antibody response after recovery and/or vaccination. To date, there are no data on the safety and efficacy of the combined vector vaccine Sputnik V in patients with CLL. Here, we analyzed and compared the magnitudes of the antibody and T cell responses after vaccination with the Sputnik V vaccine among healthy donors and individuals with CLL with different statuses of preexposure to coronavirus. We found that vaccination of the COVID-19-recovered individuals resulted in the boosting of pre-existing immune responses in both healthy donors and CLL patients. However, the COVID-19-naïve CLL patients demonstrated a considerably lower antibody response than the healthy donors, although they developed a robust T cell response. Regardless of the previous infection, the individuals over 70 years old demonstrated a decreased response to vaccination, as did those receiving anti-CD20 therapy. In summary, we showed that Sputnik V, like other vaccines, did not induce a robust antibody response in individuals with CLL; however, it provided for the development of a significant anti-COVID-19 T cell response.